Open

BLU-222-1101: Phase 1/2 Study of BLU-222 in Advanced Solid Tumors

To evaluate the safety and efficacy of BLU-222 therapy in patients with advanced solid tumors.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

The study involves blood draws, physical exams, pregnancy testing (if female), receipt of study drugs, electrocardiograms, CT and MRI scans, and questionnaires.

Incentives

Study medication.

Total length of participation:
About 43 months

Looking for Specific Volunteers

Able to participate:

You have metastatic HR positive HER2 negative breast cancer that cannot be removed by surgery.
You are able to swallow an oral medication whole.
Your cancer has progressed after receiving either Palbociclib, ribociclib, or abemaciclib in combination with hormone therapy.
You are able to receive intramuscular fulvestrant.

Not eligible if:

You have received radiation therapy for your cancer within 14 days prior to starting the study medication.
You have received any immunotherapy or other antibody therapy within 28 days prior to the first dose of study drug
You have uncontrolled heart disease.
You are pregnant or breastfeeding.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Yara Abdou
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

23-1605

ClinicalTrials.gov

NCT05252416

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.